Loading...
Loading...
Indian Pharmaceutical Exporter ยท #13 for Diclofenac ยท $4.9M export value ยท DGFT Verified
DR Reddys Laboratories Limited is the #13 Indian exporter of Diclofenac with $4.9M in export value and 98 verified shipments. DR Reddys Laboratories Limited holds a 1.3% market share in Diclofenac exports across 1 countries. The company exports 37 pharmaceutical products worth $62.4M across 17 therapeutic categories.

| Country | Value | Shipments | Share |
|---|---|---|---|
| UNITED STATES | $91.2M | 1,928 | 40.9% |
| GHANA | $19.7M | 630 | 8.8% |
| FRANCE | $18.9M | 379 | 8.5% |
| NIGERIA | $17.4M | 722 | 7.8% |
| AFGHANISTAN | $16.7M | 368 | 7.5% |
| TANZANIA | $11.8M | 237 | 5.3% |
| GUATEMALA | $10.3M | 207 | 4.6% |
| MYANMAR | $9.7M | 267 | 4.4% |
| UZBEKISTAN | $9.5M | 190 | 4.3% |
| BENIN | $4.2M | 83 | 1.9% |
India exports Diclofenac to 173 countries. The top destination is UNITED STATES (40.9%), followed by GHANA and FRANCE.
| Buyer | Country | Value | Orders |
|---|---|---|---|
| CIPLA USA INC UPS SUPPLY CHAIN SOLU | UNITED STATES | $20.5M | 990 |
| PLANET PHARMA | FRANCE | $10.1M | 202 |
| DR. REDDY'S LABORATORIES, INC | UNITED STATES | $4.7M | 93 |
| NUEVOS ETICOS NEOETHICALS, S.A. | GUATEMALA | $4.2M | 84 |
| AIM RX 3PL, LLC | UNITED STATES |
India exported $119.5M worth of Diclofenac through 15,000 shipments from 1007 suppliers to 173 countries, serving 2,731 buyers globally. DR Reddys Laboratories Limited contributes $4.9M to this total, accounting for 1.3% of India's Diclofenac exports.
DR Reddys Laboratories Limited's average Diclofenac shipment value is $50.0K per consignment, based on 98 shipments totaling $4.9M.
DR Reddys Laboratories Limited ranks #13 among 1007 Indian Diclofenac exporters with a 1.3% market share. The top 3 exporters are CIPLA LIMITED ($20.9M), TROIKAA PHARMACEUTICALS LIMITED ($16.0M), CAPLIN POINT LABORATORIES LIMITED ($15.5M). DR Reddys Laboratories Limited processed 98 shipments to 1 destination countries.
What DR Reddys Laboratories Limited must comply with to export Diclofenac to its top destination countries
Approval Process
ANDA (Abbreviated New Drug Application) for generics. Indian manufacturing site must pass FDA pre-approval inspection. Drug Master File (DMF) required for APIs.
Timeline: 10โ18 months for ANDA approval
GMP & Export Requirements
FDA cGMP compliance (21 CFR 210/211); facility inspection by FDA
Drug Listing with FDA; Export Certificate from CDSCO India; Import Alert screening via FDA PREDICT system
Note: Subject to FDA Import Alerts. Open Form 483 observations can block all exports from a facility.
Approval Process
Exporters ranked immediately above and below #13 by export value
| # | Supplier | Export Value | Shipments | Countries | Avg/Shipment |
|---|---|---|---|---|---|
| 8 | MICRO LABS LIMITED | $8.8M | 177 | 18 | $50.0K |
| 9 | DR.REDDY'S LABORATORIES LTD | $8.3M | 165 | 1 | $50.0K |
| 13 | DR REDDYS LABORATORIES LIMITED โ | $4.9M | 98 | 1 | $50.0K |
| 3 | RUBICON RESEARCH PRIVATE LIMITED | $4.7M | 93 | 1 | $50.0K |
| Port | Shipments | % Share |
|---|---|---|
| NHAVA SHEVA SEA (INNSA1) | 2,481 | 16.5% |
| JNPT/ NHAVA SHEVA SEA | 1,272 | 8.5% |
| SAHAR AIR CARGO ACC (INBOM4) | 1,186 | 7.9% |
| SAHAR AIR | 903 | 6.0% |
| JNPT | 712 | 4.7% |
| DELHI AIR CARGO ACC (INDEL4) | 679 | 4.5% |
| NHAVA SHEVA | 676 | 4.5% |
| Bombay Air | 491 | 3.3% |
DR Reddys Laboratories Limited also exports these analgesics & antipyretics products. Each links to the detailed product page.
The global pharmaceutical export landscape has been significantly influenced by recent geopolitical events. The 2026 Strait of Hormuz crisis, initiated by military conflicts involving the United States, Israel, and Iran, led to the effective halt of shipping traffic through this critical maritime route, disrupting approximately 20% of the world's daily oil supply and causing a surge in global energy prices. (en.wikipedia.org) This disruption has had a cascading effect on shipping costs and insurance premiums, directly impacting Indian pharmaceutical exporters like Dr. Reddy's, which rely on these routes for timely delivery of products to key markets.
Simultaneously, the 2025โ26 United StatesโIndia diplomatic and trade crisis, marked by the imposition of a 50% tariff on Indian exports by the U.S., has posed additional challenges. These tariffs have increased the cost of Indian pharmaceutical products in the U.S. market, potentially affecting the competitiveness of companies like Dr. Reddy's. (en.wikipedia.org)
In the European Union, compliance with the Falsified Medicines Directive (FMD) remains a critical requirement for exporters. Dr. Reddy's has been proactive in adhering to these regulations, ensuring that its products meet the stringent safety and traceability standards mandated by the EU, thereby maintaining its market access and reputation.
Compliance with international regulatory standards is paramount for Indian pharmaceutical exporters. Dr. Reddy's has demonstrated a commitment to quality by securing approvals from major regulatory bodies, including the U.S. Food and Drug Administration (FDA), the World Health Organization (WHO), and the European Medicines Agency (EMA). The company's recent Biologics License Application (BLA) submission for a proposed interchangeable biosimilar to Orenciaยฎ (abatacept) underscores its adherence to rigorous regulatory processes. (stockwatch.com)
However, the company has faced regulatory challenges, such as the tax audit decision from the Russian Federal Tax Service in January 2026, which reclassified certain marketing services as taxable, resulting in a penalty. (stocktitan.net) Such incidents highlight the complexities of operating in diverse regulatory environments and the importance of robust compliance frameworks.
DR Reddys Laboratories Limited exports 37 products worth $62.4M. Beyond Diclofenac, top products include Omeprazole, Metoprolol, Clopidogrel, Fexofenadine, Esomeprazole. View the complete DR Reddys Laboratories Limited profile for full portfolio analysis.
Latest developments and market context
Detailed market intelligence for Diclofenac โ including regulatory updates, trade policy changes, and competitive landscape analysis โ will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Pharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormareAll trade data is sourced from Indian Customs (DGFT) official shipping bill records โ the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Access shipment-level details, pricing data, buyer connections, and competitive analysis for DR Reddys Laboratories Limited's Diclofenac exports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
DR Reddys Laboratories Limited
Full Company Profile โ
37 products ยท $62.4M total trade ยท 17 categories
| $4.1M |
| 82 |
| HEKO PHARMACY LTD | TANZANIA | $2.7M | 54 |
| SHAMS NOORI PHARMA TRADING COMPANY | AFGHANISTAN | $1.4M | 29 |
| RELIABLE HEALTHCARE LOGISTICS LLC | UNITED STATES | $400.0K | 8 |
| UNIVERSAL CO. LTD. | MYANMAR | $400.0K | 8 |
| SFS PHARM LLC | UZBEKISTAN | $350.0K | 7 |
India's Diclofenac is purchased by 2,731 buyers worldwide. The top buyer is CIPLA USA INC UPS SUPPLY CHAIN SOLU (UNITED STATES), followed by PLANET PHARMA and DR. REDDY'S LABORATORIES, INC.
Drug registration under NAFDAC guidelines. WHO-type CPP from India required.
Timeline: 6โ18 months
GMP & Export Requirements
WHO GMP compliance; NAFDAC conducts overseas plant inspections
Certificate of Pharmaceutical Product (CPP) from CDSCO India; NAFDAC import permit
Note: India is the largest pharma supplier to Nigeria. NAFDAC has intensified Indian site inspections.
Regulatory information is provided for general reference based on publicly available guidelines. Requirements vary by formulation, dosage form, and therapeutic classification. Exporters should consult qualified regulatory affairs professionals for case-specific guidance.
| 15 |
| SOCOMED PHARMA PRIVATE LIMITED |
| $3.2M |
| 150 |
| 11 |
| $21.2K |
DR Reddys Laboratories Limited ranks #13 among 1007 Indian Diclofenac exporters. Average shipment value of $50.0K compared to the market average of $118.7K. The closest competitors by value are MICRO LABS LIMITED and DR.REDDY'S LABORATORIES LTD.
Verify manufacturer licensing and export certifications with the official agencies above.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 173+ countries, 2,731+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Access shipment-level records, pricing trends, and buyer contacts for DR Reddys Laboratories Limited.
Request DemoView Pricing โTrade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Diclofenac. For current shipment-level data, contact TransData Nexus.